當(dāng)前位置：首頁 JCRQ1 期刊介紹(非官網(wǎng))

Pediatric DrugsSCIE

國際簡(jiǎn)稱：PEDIATR DRUGS 參考譯名：兒科藥物

中科院分區(qū)
3區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：1174-5878; E-ISSN：1179-2019; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：NEW ZEALAND; 出版商：Springer International Publishing; 出版語言：English; 出版周期：6 issues per year; 出版年份：1999; 研究方向：PEDIATRICS-PHARMACOLOGY & PHARMACY

評(píng)價(jià)信息：: 影響因子：3.4; H-index：55; CiteScore指數(shù)：7.2; SJR指數(shù)：1.017; SNIP指數(shù)：1.263

發(fā)文數(shù)據(jù)：: Gold OA文章占比：29.27%; 研究類文章占比：44.23%; 年發(fā)文量：52; 自引率：0; 開源占比：0.2356; 出版撤稿占比：0; 出版國人文章占比：0.02; OA被引用占比：0.2235...

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡(jiǎn)介Pediatric Drugs期刊介紹

Pediatric Drugs promotes the optimization and advancement of all aspects of pharmacotherapy for healthcare professionals interested in pediatric drug therapy (including vaccines). The program of review and original research articles provides healthcare decision makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology and the care of children and adolescents. The Journal includes:

-overviews of contentious or emerging issues.

-comprehensive narrative reviews of topics relating to the effective and safe management of drug therapy through all stages of pediatric development.

-practical reviews covering optimum drug management of specific clinical situations.

-systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.

-Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in the pediatric population.

-original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pediatric Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

期刊簡(jiǎn)介Pediatric Drugs期刊介紹

《Pediatric Drugs》自1999出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間： 12周，或約稿
醫(yī)學(xué)
PEDIATRICS
SCIE
中科院3區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Pediatric Drugs Cite Score數(shù)據(jù)

CiteScore：7.2
SJR：1.017
SNIP：1.263

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Pediatrics, Perinatology and Child Health	Q1	27 / 330	91%
大類：Medicine 小類：Pharmacology (medical)	Q1	50 / 272	81%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Pediatric Drugs 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	3區(qū)	PEDIATRICS 兒科 PHARMACOLOGY & PHARMACY 藥學(xué)	2區(qū) 3區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Pediatric Drugs JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PEDIATRICS	SCIE	Q1	19 / 186	90.1%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q2	105 / 354	70.5%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PEDIATRICS	SCIE	Q1	39 / 186	79.3%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	78 / 354	78.11%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計(jì)

國家/地區(qū)數(shù)量
USA72
Italy20
England13
Netherlands10
Belgium9
Canada9
Australia8
France6
New Zealand6
CHINA MAINLAND5

本刊中國學(xué)者近年發(fā)表論文

1、Trends in Adverse Drug Reactions Among Children: Evidence from Jiangsu Province of China, 2010-2019
Author: Xue, Hui; Li, Ming; Fan, Lijun; Du, Wei; Zou, Jianjun

Journal: PEDIATRIC DRUGS. 2023; Vol. 25, Issue 1, pp. 97-114. DOI: 10.1007/s40272-022-00539-6
2、Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives
Author: Zhao, Jinxia; Bian, Jialu; Zhao, Yinyu; Li, Yuanyuan; Liu, Boyu; Hao, Xu; He, Shiyu; Huang, Lin

Journal: PEDIATRIC DRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40272-023-00560-3
3、Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis
Author: Noor B. Almandil, Ying Liu, Macey L. Murray, Frank M. C. Besag, Katherine J. Aitchison, Ian C. K. Wong

Journal: PEDIATRIC DRUGS, 2013, Vol.15, 139-150, DOI:10.1007/s40272-013-0016-6
4、The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma
Author: Xin Xiao, Wei Wang, Zhen Wang

Journal: PEDIATRIC DRUGS, 2014, Vol.16, 503-512, DOI:10.1007/s40272-014-0095-z
5、Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial
Author: Shuanghong Luo, Mengdong Ran, Qiuhong Luo, Min Shu, Qin Guo, Yu Zhu, Xiaoping Xie, Chongfan Zhang, Chaomin Wan

Journal: PEDIATRIC DRUGS, 2017, Vol.19, 479-486, DOI:10.1007/s40272-017-0237-1
6、Effectiveness and Safety of Different Once-Daily Doses of Adrenocorticotropic Hormone for Infantile Spasms
Author: Jinghua Yin, Qianjin Lu, Fei Yin, Ying Wang, Fang He, Liwen Wu, Lifen Yang, Xiaolu Deng, Chen Chen, Jing Peng

Journal: PEDIATRIC DRUGS, 2017, Vol.19, 357-365, DOI:10.1007/s40272-017-0225-5
7、Effect of Levocarnitine on the Therapeutic Efficacy of Conventional Therapy in Children with Dilated Cardiomyopathy: Results of a Randomized Trial in 29 Children
Author: Yuwen Wang, Yi Xu, Runmei Zou, Lijia Wu, Ping Liu, Hong Yang, Zhenwu Xie, Cheng Wang

Journal: PEDIATRIC DRUGS, 2018, Vol.20, 285-290, DOI:10.1007/s40272-018-0284-2
8、Method Development for Clinical Comprehensive Evaluation of Pediatric Drugs Based on Multi-Criteria Decision Analysis: Application to Inhaled Corticosteroids for Children with Asthma
Author: Yuncui Yu, Lulu Jia, Yao Meng, Lihua Hu, Yiwei Liu, Xiaolu Nie, Meng Zhang, Xuan Zhang, Sheng Han, Xiaoxia Peng, Xiaoling Wang

Journal: PEDIATRIC DRUGS, 2017, Vol.20, 195-204, DOI:10.1007/s40272-017-0278-5